Airain Ltd’s Genomic Health, Inc. GHDX Stock Holding History

Airain Ltd’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$472K	Buy	14,489 +5,428	+60%	+$172K	0.02%	553
2017 Q1	$285K	Buy	+9,061	New	+$268K	0.01%	632
2016 Q4	–	Sell	-13,734	Closed	-$397K	–	927
2016 Q3	$397K	Buy	+13,734	New	+$383K	0.02%	469

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Airain Ltd's GHDX Position: Q2 2017 in Review

Airain Ltd increased its Genomic Health, Inc. (GHDX) stake by 60% in Q2 2017, buying an estimated $172K and bringing the position to 14,489 shares worth $472K. The position accounts for 0.02% of the portfolio, ranked #553.

Airain Ltd first reported a position in GHDX in Q3 2016 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold GHDX as of Q2 2017.

Airain Ltd held 14,489 shares of Genomic Health, Inc. worth $472K as of Q2 2017.
Airain Ltd bought 5,428 Genomic Health, Inc. shares in Q2 2017, an estimated $172K.
Genomic Health, Inc. made up 0.02% of Airain Ltd's portfolio in Q2 2017, its #553 holding.
Airain Ltd first reported a position in Genomic Health, Inc. in Q3 2016 and has held it in 3 quarters since.
124 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.